PDAB Survey: Individuals with Scientific or Medical Training and Safety Net Providers
The Prescription Drug Affordability Board (PDAB) is seeking input from individuals with scientific or medical training and safety net providers to provide input on one of the following prescription drugs: 
  • Enbrel
  • Genvoya
  • Cosentyx
  • Stelara
  • Trikafta
This survey should take 10-15 minutes to complete. It is divided into three sections: Personal Information,  Health Effects of the Prescription Drug, and Financial Effects of the Prescription Drug. 

The PDAB will use the information you provide here as part of the affordability review process to determine if a prescription drug is unaffordable for Colorado consumers. Surveys should be completed by October 12.
Sign in to Google to save your progress. Learn more
Personal Information
Name *
Email address *
Have you attended, or do you plan to attend, a public input session for individuals with scientific or medical training?  *
After you complete the survey, Board staff may have follow up questions for you. Do you consent to staff reaching out to you via email after you complete the survey? 
Clear selection
I am answering this survey as an individual with scientific or medical training who mainly utilizes my expertise:  *
Required
My expertise directly relates to patients who live:  *
Required
Which prescription drug are you providing comments on today?  *
Health Effects of the Prescription Drug
Please list the conditions that are treated by the prescription drug for which you are providing expertise. 
What is the impact of this condition(s) on your patients? 
From your experience, how is this drug used in standard medical practice? 
From your experience, describe any off-label usage of this drug. 
In your experience, what are the health benefits of this drug? 
In your experience, what are the health disadvantages of this drug? 
From your experience, are there any common therapeutic alternatives to this prescription drug? If so, please list them. 
In your experience, what are the benefits or disadvantages between therapeutic alternatives and this prescription drug?
Financial Effects of the Prescription Drug
In your experience, do patients raise financial concerns when being prescribed this prescription drug? 
Do you discuss this drug's expense with patients when prescribing? 
Clear selection
When do you discuss financial effects with patients related to this drug? 
Clear selection
At the point of prescribing, do you discuss any of the following with your patients related to this prescription drug? Select all that apply. 

In your experience, have utilization management policies (e.g., insurance requirements related to step therapy or prescription drug formulary tiers) impacted your patients' ability to access this drug? 

Clear selection
If you are a safety net provider, does your clinic/facility provide this prescription drug to patients? If not, why?
If you are a safety net provider, do you receive a 340B discount for this prescription drug? 
Clear selection
In your experience, are there any other financial effects of the condition and prescription drug you think the Board should consider? 
Submit
Clear form
Never submit passwords through Google Forms.
This form was created inside of State.co.us Executive Branch. Report Abuse
Google Forms